Seeking Alpha

ARRY
  Array BioPharma Inc. - NASDAQ

11/27/2014, 8:07 AM ET
  • Roy Manning III | Send Message 8 May 2012

    ARRY is a good buy. Expecting $20 million in milestone payments by end of year. Payments from partners keep this stock profitable.
    Reply
      ARRY vs. ETF Alternatives
      Company Description
      Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
      Sector: Services
      Country: United States